Evidence map›Paper›PMID 27766772›Full record

ArticleThoracic cancer2016

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutation.

Aimi Huang, Rong Li, Jikai Zhao, Xiaofei Wang, Bo Jin, Yanjie Niu, Jie Zhang, Liyan Jiang, Baohui Han

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Aimi HuangDepartment of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China.
Rong LiDepartment of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China.
Jikai ZhaoDepartment of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China.
Xiaofei WangDepartment of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China.
Bo JinDepartment of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China.
Yanjie NiuDepartment of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China.
Jie ZhangDepartment of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China.
Liyan JiangDepartment of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China.
Baohui HanDepartment of Respiratory Medicine, Shanghai Chest Hospital, Shanghai, China.
Shanghai Chest Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article demonstrates a case of a lung adenocarcinoma patient in stage IV harboring an epidermal growth factor receptor (EGFR) 19 exon deletion mutation treated with 500 mg/m

Indexed as

AdultAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCisplatinDisease ProgressionErbB ReceptorsFemaleGefitinibHumansLung NeoplasmsMutationNeoplasm MetastasisPemetrexedProtein Kinase InhibitorsQuinazolinesTreatment OutcomeCisplatinEGFR protein, humanErbB ReceptorsGefitinibPemetrexedProtein Kinase InhibitorsQuinazolinesChemotherapyEGFR sensitivemutationnon-small cell lung cancertarget therapy

Identifiers

PMID27766772
PMCPMC5193016
OpenAlexW2470257114

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.